GSK board conflict of interest
Executive Summary
Case Western Reserve University School of Medicine Dean Ralph Horwitz will not join GlaxoSmithKline's board as a non-executive director due to a potential conflict of interest concerning a decongestant component of a withdrawn SmithKline Beecham product. Horwitz was an investigator in a study linking phenylpropanolamine to hemorrhagic stroke. Over-the-counter medicines containing PPA were withdrawn from the market in 2000, prompting lawsuits against GSK and other drug makers (1"The Pink Sheet" Nov. 13, 2005, p. 25)...
You may also be interested in...
Knoll Meridia Discount Program Uses Advance PCS Pharmacy Card
Advance PCS will manage Knoll Pharmaceutical's discount program for its weight-loss product Meridia.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.